December 14, 2009 08:30 ET

Market Pulse Breaking News Alert for Monday, December 14, 2009: RMCP - RevMed Launches RevVac Safety Syringe Mass Manufacturing Process and Revenue on Target to Hit $14.8 Million in 2010!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse

ATLANTA, GA--(Marketwire - December 14, 2009) - Market Pulse News Alert for this AM, Stocks to Watch are: Revolutions Medical Corporation (OTCBB: RMCP), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Blue Gem Enterprise (OTCBB: BGEM) and Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC).

Investors need to be watching Revolutions Medical Corporation (OTCBB: RMCP) this AM! Revolutions Medical Corporation (RevMed) is engaged in the design, development, commercialization and acquisition of new products and tools to make healthcare safer and less expensive. RevMed's products include safety-engineered medical devices (SEMDs) and the flagship RevVac safety syringe (FDA Approved), safety blood drawing devices, and safety IV catheters. The products use a proprietary patented technology in which a vacuum causes the needle to retract into the barrel of the syringe or device after an injection is administered or blood is drawn. RevMed owns the patents to manufacture the disposable retractable syringe and phlebotomy device. The world market for SEMDs is projected to exceed $2 billion this year and is forecasted to maintain a 20% annual growth rate in the near term. RevMed also offers RevColor, RevDisplay and Rev3D software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D, and automatic segmentation of images. These tools will enhance the physician's diagnostic confidence in an industry that is growing at 10% - 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceeds $3.5 billion. The company is continually looking for new and improved technology through internal product development and acquisition. The company's future growth will be powered by new product line introductions, and the material expansion of existing successful lines. RevMed's Breast Biopsy System (BBS), stereotactic (minimally invasive) image-based localization technology, is one of those product lines pursuing the $9.5 billion breast screening industry. RevMed's Breast Biopsy System, the MRI enhancement software and the SEMDs will be launching in the next 18 months. All three markets are immediately addressable and total more than $14 billion. RevMed recently introduced its proprietary suite of MRI software products at the Radiology Society of North America annual meeting with great success. Radiologists and universities world-wide received presentations at the RMCP booth. A number of these contacts could play an important role in the company's ongoing efforts to clinically validate specific applications of its MRI tools prior to the 2010 commercial launch. Never has health care been a hotter issue, and the focus of the conversation is on increased safety at dramatically reduced cost. Revolutions Medical has the formula for success, and one that has them immediately positioned for a high growth future. With 3 recurring revenue business lines with blended gross margins projected to exceed 50% and anticipated profitability in its first full year of operations, Revolutions Medical Corporation is poised to become a significant player in the healthcare and medical devices industry! RMCP has had several excellent press releases out lately and one again before today's opening bell announcing that it has initiated the mass manufacturing process for the RevVac safety syringe, which is already FDA approved! The company also said it's on pace to meet its Q2 '10 sales launch goal and $14.8 million 2010 revenue projection! This could be great news for investors!

Revolutions Medical Corporation (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today announced that it has initiated the mass manufacturing process for the RevVac safety syringe, which is already FDA approved. By hitting its primary milestone, RevMed satisfies its previously announced commitment to begin production in Q4 '09. It also stays on pace to meet its Q2 '10 sales launch goal and $14.8 million 2010 revenue projection.

"After years in developing what we believe is the world's best safety syringe, we are extremely pleased to announce that the plan is now reality -- we have launched the mass manufacturing process for the RevVac safety syringe," stated Revolutions Medical CTO Richard Theriault. "This constitutes the next step toward full scale high volume production and commercialization. With this first phase we will 1) provide market-ready samples and 2) complete the steps necessary to ensure ultimate delivery of a high quality, high volume manufacturing solution. We have been working closely with the team at Goddard Technologies (www.goddardtech.com) -- the group responsible for the recent crucial product refinements -- towards this, our primary pre-sales milestone. We remain precisely on pace with our stated goals, and we can now demonstrate tangible progress toward bringing the much-anticipated RevVac to market in Q2 '10."

Andrew Goddard, President of Goddard Technologies, stated, "We are pleased to be working with Revolutions Medical on the first phase of the RevVac Safety Syringe mass manufacturing process. The RevVac design is unique and elegant as an easy to use, single handed vacuum safety syringe. That we could contribute to a product of such high caliber is a source of great pride for Goddard Technologies."

About Revolutions Medical Corporation (www.revolutionsmedical.com)

RevMed's products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

Stocks in the news, and acting well as of late, include: Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Blue Gem Enterprise (OTCBB: BGEM) and Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated twenty five thousand restricted shares of Revolutions Medical Corporation by the company. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.